Preferred Label : KRAS G12C Inhibitor IBI351;
NCIt synonyms : KRAS G12C Inhibitor GFH925;
NCIt definition : An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation, G12C,
with potential antineoplastic activity. Upon oral administration, KRAS G12C inhibitor
IBI351 selectively targets, binds to and inhibits the activity of the KRAS G12C mutant,
thereby inhibiting KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS
family of oncogenes, serves an important role in cell signaling, division and differentiation.
Mutations of KRAS may induce constitutive signal transduction leading to tumor cell
growth, proliferation, invasion, and metastasis.;
Molecule name : GFH 925; GFH-925; IBI-351; IBI 351;
NCI Metathesaurus CUI : CL1770685;
Origin ID : C182070;
UMLS CUI : C5783443;
Semantic type(s)
- concept_is_in_subset
- has_target
